Option chain shows key data for Allena Pharmaceuticals Inc's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Allena Pharmaceuticals Inc.

Allena Pharmaceuticals Inc (OTC:ALNAQ) Stock, Option Chain

Allena Pharmaceuticals Inc

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOWL#NASDAQ">HOWL</a>) with a Buy and maintains $15 price target.

News

Price Target

Reiteration

Analyst Ratings

HOWL

HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target

HC Wainwright &amp; Co. analyst Yi Chen reiterates Anixa Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) with a Buy and maintains $7 price target.

ANIX

HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $7 Price Target

Management

Adtalem Global Education Inc. Common Stock

ATGE

Adtalem Global Education Says Steve Beard, President And CEO, Was Unanimously Elected By Board To The Additional Position Of Board Chairman, Effective Immediately

Prominent venture capitalist David Sacks has predicted a high <a href="https://www.benzinga.com/markets/equities/24/10/41351251/trump-says-google-has-a-lot-of-power-but-stops-short-of-endorsing-a-break-up">likelihood of legal action</a> or a breakup of Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google in the next U.S. administration under Donald Trump.
What Happened: In an episode of the&nbsp;All-In&nbsp;podcast that was released on Saturday, Sacks stated that Google, which holds monopolies in search, advertising, and YouTube, should be dismantled.
&#8220;Google should be broken up,&#8221; he said, underscoring the need to address the company&#8217;s dominance in these key areas. 
Sacks also expressed confidence that the likelihood of a legal challenge or antitrust lawsuit against the tech giant is high, particularly with the prospect of a Trump administration in the future.
"What are the odds that this is pursued in the next administration? I'd say high," he added.
See Also:&nbsp;<a href="https://www.benzinga.com/news/retail-sales/24/11/42024288/consumer-tech-news-november-11-15-apple-plans-to-launch-an-ai-wall-tablet-meta-plans-to-introduce-ads-on-threads-more?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Consumer Tech News (November 11-15): Apple Plans To Launch An AI Wall Tablet, Meta Plans To Introduce Ads On Threads &amp; More</a>
The venture capitalist also said that while Mark Zuckerberg-led Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) faces challenges, there is less urgency to break it up.
Instead, Meta's issues are more focused on content moderation, especially its role in <a href="https://www.benzinga.com/general/biotech/24/08/40575260/mark-zuckerberg-reveals-biden-administration-pressured-meta-platforms-to-censor-certain-covid-19-">censoring free speech</a> during the 2020 election cycle related to Hunter Biden stories.
&#8220;But I do think, though, that Congress should investigate or continue investigating what went wrong there and what exactly is the involvement of the intelligence community and the deep state in the censorship request that we saw exposed by the Twitter files,&#8221; Sacks said.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Google has been under scrutiny for its monopolistic practices.
On Monday, it was reported that the <a href="https://www.benzinga.com/news/legal/24/11/42053249/google-could-lose-chrome-browser-in-dojs-latest-antitrust-move">U.S. Department of Justice</a>&nbsp;prepared to request a court order to force Google to divest its Chrome browser, following a ruling that found Google guilty of illegally monopolizing the search market.
As the DOJ&#8217;s final proposed remedies approach on Nov. 20, JPMorgan analyst Doug Anmuth anticipates potential headline risk but views this as an <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42036010/alphabet-on-trial-doj-remedies-loom-but-analyst-sees-20-upside-as-discount-to-meta-narrows">opportunity for greater clarity</a>.&nbsp;
He continues to hold an Overweight rating on the Alphabet stock, setting a price target of $212, which suggests a 20% upside from its current price.
Last month, Alphabet reported <a href="https://www.benzinga.com/news/earnings/24/10/41611263/alphabet-q3-earnings-highlights-revenue-beat-eps-beat-google-cloud-up-35-momentum-across-the-compan">third-quarter revenue</a> of $88.27 billion, marking a 15% year-over-year increase and surpassing the Street consensus estimate of $86.31 billion.
At the time, CEO Sundar Pichai had&nbsp;cautioned&nbsp;that the DOJ's proposals could lead to &#8220;<a href="https://www.benzinga.com/news/24/10/41616230/sundar-pichai-admits-doj-proposals-could-have-unintended-consequences-google-mapping-out-plan-b-in-c">unintended consequences</a>.&#8221;
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Trump&#039;s market impact: Bitcoin, M&amp;A, IPOs + transition picks; Polymarket CEO raided by FBI" width="500" height="281" src="https://www.youtube.com/embed/0CBMlzHo0AU?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Price Action: On Monday, Alphabet&#8217;s Class A stock rose 1.63%, closing at $175.30, while Class C stock gained 1.67% to close at $176.80.
However, in pre-market trading on Tuesday, Alphabet&#8217;s Class A stock fell 0.63% to $174.20, and Class C stock declined 0.89% to $175.22, according to <a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42022124/t-mobile-hit-by-chinese-hackers-after-rivals-att-verizon-suffer-breach-report?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">T-Mobile Hit By Chinese Hackers After Rivals AT&amp;T, Verizon Suffer Breach: Report</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Markets

Tech

AAPL

GOOG

GOOGL

'Google Should Be Broken Up,' VC David Sacks Foresees High Odds Of Antitrust Lawsuit Or Breakup Under Donald Trump's Administration

AKAM

Akamai Extends Segmentation Solution, Akamai Guardicore Segmentation, To Support Agentless Enforcement For Cloud Native Resources In Amazon Web Services

Comstock Fuels Corporation ("Comstock Fuels"), of an amendment to its exclusive license agreement with RenFuel K2B AB ("RenFuel") for use of RenFuel's patented catalytic esterification process to refine Comstock Fuels' proprietary BioleumTM biointermediates. The amendment expanded the territory from North America, Central America, and South America to include Australia, New Zealand and Vietnam to facilitate ongoing project development by licensees of Comstock Fuels broader lignocellulosic biomass refining process.

LODE

Comstock Fuels Expands License Agreement With Renfuel K2B To Include Australia, New Zealand, And Vietnam

On Monday, November 18, U.S. markets ended mixed, partially recovering losses as investors awaited Nvidia&#8217;s highly anticipated Q3 earnings, seen as a key gauge of AI-driven market momentum. 
Tesla shares climbed on optimism over potential policy shifts under the incoming Trump administration. While analysts note a widening focus beyond Nvidia, its influence on market sentiment remains significant.
In economic data, the NAHB/Wells Fargo Housing Market Index rose to 46 in November, marking its highest level in seven months, up from 43 in October.
S&amp;P 500 sectors rose Monday, led by energy, communication services, and consumer discretionary stocks, while industrials declined.
The Dow Jones Industrial Average was down 0.13% and closed at 43,389.60, the S&amp;P 500 gained 0.39% to 5,893.62, and the Nasdaq Composite rose 0.60% to finish at 18,791.81.
Asia Markets Today
<ul>
<li>On Tuesday, Japan&#8217;s Nikkei 225 gained 0.45% and ended the session at 38,405.00, led by gains in the Paper &amp; Pulp, Steel, and Warehousing sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 rose 0.89% and ended the day at 8,374.00, led by gains in the Gold, IT, and Telecoms Services sectors.</li>
<li>India&#8217;s Nifty 50 closed 0.07% higher at 23,470.45, and Nifty 500 up 0.23% at 21,950.85, led by gains in the Auto, Real Estate and Consumer Durables sectors.</li>
<li>China&#8217;s Shanghai Composite gained 0.67% to close at 3,346.01, and the Shenzhen CSI 300 rose 0.67%, finishing the day at 3,976.89.</li>
<li>Hong Kong&#8217;s Hang Seng gained 0.44% and closed the session at 19,663.67.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 index was down 1.47%.</li>
<li>Germany&#8217;s DAX slid 1.07%.</li>
<li>France&#8217;s CAC fell 1.32.</li>
<li>FTSE 100 index traded lower by 0.50%</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 0.88% at $68.56/bbl, and Brent was down 0.75% at $72.75/bbl.</li>
<li>Oil prices dipped as Norway&#8217;s Johan Sverdrup oilfield resumed production, offsetting geopolitical tensions and Kazakhstan&#8217;s output cut. A stronger U.S. dollar also pressured prices while investors monitored escalating Russia-Ukraine tensions and weakening market structure signals.</li>
<li>Natural Gas rose 0.30% to $2.982.</li>
<li>Gold was trading higher by 0.94% at $2,639.20, Silver gained 0.92% to $31.508, and Copper fell 0.45% to $4.1015.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures declined 0.53%, S&amp;P 500 futures were down 0.38% and Nasdaq 100 futures fell 0.27%.
Forex at 05:30 AM ET
The U.S. dollar index gained 0.14% to 106.42, the USD/JPY was down 0.66% to 153.63, and the USD/AUD rose 0.17% to 1.5391.
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Up, Europe Markets Slip; Oil Prices Pressured While Gold Strengthens - Global Markets Today While US Slept

GRFS

Brookfield Capital Partners Confirmed Request for Due Diligence Information; Considers €10.50/Share for Grifols Class A Shares; €7.62/Share for Class B Shares

Management expects a double-digit growth year over year for full year SECaaS revenue and SECaaS ARR.

Guidance

ALLT

Allot Expects To Remain Around Breakeven On Non-GAAP Operating Profit Basis And To Generate Positive Operating Cash Flow For Q4

<ul>
<li>2025 comparable EBITDA expected to be approximately $10.7 to $10.9 billion</li>
<li>Announced four new growth projects, totaling&nbsp;approximately $1.5 billion&nbsp;of gross capital expenditures, aligned with increasing demand for natural gas and nuclear power generation</li>
</ul>

TC Energy To Host Its Investor Day, To Outline Its Strategic Vision And Growth Outlook; Announces Four New Growth Projects Across Portfolio

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) with a Buy and maintains $9 price target.

RANI

HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $9 Price Target

Grifols To Hold Extraordinary Meeting Tuesday To Consider €10.50/Share For Grifols Class A Shares From Brookfield Capital Partners

Chinese EV maker&nbsp;XPeng&nbsp;Inc&nbsp;(NYSE:&nbsp;XPEV) reported&nbsp;fiscal third-quarter&nbsp;sales growth of 18.4% year-on-year,&nbsp;to 10.10 billion Chinese Yuan ($1.44 billion), topping the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42056000/xpeng-reports-third-quarter-2024-unaudited-financial-results" rel="noreferrer noopener">analyst consensus estimate of $1.38 billion</a>.&nbsp; Total revenues&nbsp;increased 24.5% sequentially.
Adjusted&nbsp;net loss per ADS&nbsp;of 1.62 Chinese Yuan beat the&nbsp;analyst consensus estimate for a loss of&nbsp;1.71 Chinese Yuan. In USD terms, the adjusted earnings per ADS was a loss of 23 cents, which beat the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus estimate of 27 cents</a> loss. The stock price climbed after the print.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42041663/walmarts-black-friday-cyber-monday-huge-deals-on-electronics-toys-and-more" rel="noreferrer noopener">Walmart Gears Up For Black Friday, Cyber Monday Specials: Major Discounts On Apple MacBooks, Sony TVs</a>
The&nbsp;Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)&nbsp;rival&#8217;s quarterly vehicle deliveries increased 16.3% year-on-year to 46,533.&nbsp;XPeng&#8217;s physical sales network&nbsp;had 639 stores, covering 206 cities as of September 30, 2024.
XPeng&#8217;s&nbsp;self-operated&nbsp;charging&nbsp;station&nbsp;network&nbsp;reached 1,557 stations&nbsp;as of&nbsp;September 30, 2024.
Revenues from vehicle sales increased 12.1% Y/Y to $1.25 billion. Gross margin was 15.3%&nbsp;versus&nbsp;(2.7)% a year ago. Vehicle margin was 8.6%&nbsp;versus&nbsp;(6.1)% a year ago, primarily attributable to the cost reduction and the improvement in&nbsp;the model product mix.&nbsp;
Operating&nbsp;loss for the quarter was $0.26 billion.&nbsp;The&nbsp;company held $5.09 billion in cash and equivalents&nbsp;as of September 30, 2024.
Chairman and CEO of XPENG, Mr. Xiaopeng He, highlighted the company&#8217;s transformed core competencies and execution capabilities, emphasizing that the successful launch of the M03 and P7+ marks the start of a strong growth cycle driven by significant product launches.
He expressed confidence in leading XPENG to establish itself as a global leader in AI-driven automotive technology and accelerating the widespread adoption of AI in mobility.
Dr. Hongdi Brian Gu, Vice Chairman and Co-President of XPENG, noted that technology-driven cost reductions and significant quarter-over-quarter volume growth led to a record-high gross margin of 15.3%, marking the fifth consecutive quarterly improvement.
He emphasized that the significant product cycle will drive sales volume growth while strengthening gross profit and cash flow. This financial stability will enable continued investments in AI technology R&amp;D, ensuring superior products and services for customers.
Outlook: XPeng&nbsp;expects fourth-quarter vehicle deliveries&nbsp;of&nbsp;87,000–91,000, up 44.6%–51.3% year-on-year.
The company expects fourth-quarter revenue of 15.3 billion&nbsp;Chinese Yuan–16.2 billion Chinese Yuan, representing a year-on-year increase of 17.2%–24.1%,&nbsp;versus the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of 14.77 billion Chinese Yuan</a>.
Price Action: At the last check on Tuesday, XPEV stock traded higher by 4.46% to $13.59 premarket.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42038673/netflix-scores-big-beyonce-set-to-headline-nfl-christmas-halftime-show" target="_blank" rel="noreferrer noopener">Netflix Scores Big: Beyoncé Set To Headline NFL Christmas Halftime Show</a></li>
</ul>
Photo via Shutterstock

Earnings

Movers

TSLA

XPEV

XPeng Q3 Earnings: Revenue Beat, 16% Deliveries Growth, CEO Eyes AI Leadership And More

TSEM

Tower Semiconductor Reveals Start Of Volume Production Of 1.6 Tbps Silicon Photonic Products For Multiple Lead Customers Based On Its Latest Silicon Photonics Platform

HC Wainwright &amp; Co. analyst Mike Colonnese maintains Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Buy and raises the price target from $17 to $18.

BTDR

HC Wainwright & Co. Maintains Buy on Bitdeer Technologies, Raises Price Target to $18

Marriott Reports Accelerated Growth In Its Branded Residential Portfolio In The Europe, Middle East & Africa Region

Atour Lifestyle Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAT#NASDAQ">ATAT</a>) .

ATAT

Atour Lifestyle Holdings Sees FY2024 Total net revenues to increase by 48% to 52% YoY.

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Bit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) with a Buy and maintains $7 price target.

BTBT

HC Wainwright & Co. Reiterates Buy on Bit Digital, Maintains $7 Price Target

NESR

National Energy Services Q3 Adjusted EPS $0.31 Up From $0.21 YoY, Sales $336.2M Up From 300.08M YoY

<ul>
<li>Under the terms of the agreement, MSN will not be able to sell a generic version of BRUKINSA earlier than June 15, 2037, subject to potential acceleration or extension under certain customary circumstances. The composition of matter patent for BRUKINSA, expiring in April 2034, was not challenged by MSN in the litigation.</li>
<li>The settlement resolves all patent litigation brought by BeiGene against companies that sought to market generic versions of BRUKINSA. BeiGene and Sandoz Inc. previously filed a joint stipulation to dismiss patent litigation brought by BeiGene in response to Sandoz's ANDA seeking approval to market a generic version of BRUKINSA.</li>
</ul>

Biotech

Large Cap

Health Care

Legal

General

BGNE

BeiGene Has Entered Into A Settlement Agreement With MSN Pharmaceuticals And MSN Laboratories Private Resolving Patent Litigation Related To MSN's Abbreviated New Drug Application Seeking Approval To Market A Generic Version Of Brukinsa (Zanubrutinib) In US

Comments

Allena Pharmaceuticals Inc

Allena Pharmaceuticals Inc (ALNAQ) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga